Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | curities Exchange Act of 1934, as amended. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 15.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 09.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | sociated with, the reduction in workforce. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 30.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 01.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 14.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 08.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rding the Merger and the information set forth in Item 5.02 of this Current Report on Form 8-K regarding the Board of Di |
Stammdaten
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Unternehmen & Branche
| Name | Carisma Therapeutics Inc. |
|---|---|
| Ticker | CARM |
| CIK | 0001485003 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 25.107 USD |
| Beta | 3,50 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 45,300,000 | 44,717,000 | 1.07 | 6,554,000 | |
| 2025-06-30 | 10-Q | 3,700,000 | -9,774,000 | -0.23 | 5,012,000 | |
| 2025-03-31 | 10-Q | 3,700,000 | -9,266,000 | -0.22 | 15,953,000 | |
| 2024-12-31 | 10-K | 19,600,000 | -60,477,000 | -1.46 | 30,458,000 | |
| 2024-09-30 | 10-Q | 3,400,000 | -12,702,000 | -0.31 | 42,058,000 | |
| 2024-06-30 | 10-Q | 9,200,000 | -11,162,000 | -0.27 | 59,339,000 | |
| 2024-03-31 | 10-Q | 3,400,000 | -18,978,000 | -0.46 | 73,795,000 | |
| 2023-12-31 | 10-K | 14,900,000 | -86,879,000 | -2.59 | 89,554,000 | 26,532,000 |
| 2023-09-30 | 10-Q | 3,800,000 | -21,403,000 | -0.53 | 106,784,000 | 46,298,000 |
| 2023-06-30 | 10-Q | 3,600,000 | -19,876,000 | -0.49 | 133,013,000 | 66,705,000 |
| 2023-03-31 | 10-Q | 3,200,000 | -24,642,000 | -1.93 | 156,132,000 | 86,070,000 |
| 2022-12-31 | 10-K | 9,800,000 | -61,226,000 | -28.77 | 72,153,000 | -157,065,000 |
| 2022-09-30 | 10-Q | 2,578,000 | -18,327,000 | -8.37 | 199,724,000 | 165,029,000 |
| 2022-06-30 | 10-Q | 2,703,000 | -14,848,000 | -7.20 | 176,163,000 | 142,358,000 |
| 2022-03-31 | 10-Q | 822,000 | -11,312,000 | -5.49 | 225,840,000 | 172,797,000 |
| 2021-12-31 | 10-K | -336,000 | 0.00 | 240,747,000 | 171,710,000 | |
| 2021-09-30 | 10-Q | 71,674,000 | 0.36 | 235,671,000 | 161,008,000 | |
| 2021-06-30 | 10-Q | -25,442,000 | -0.15 | 241,047,000 | 49,349,000 | |
| 2021-03-31 | 10-Q | -55,512,000 | -0.35 | 186,414,000 | 9,270,000 | |
| 2020-12-31 | 10-K | -22,397,000 | -0.19 | 122,823,000 | -9,227,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-07 | Klichinsky Michael | Officer, Chief Scientific Officer | Open Market Sale | -56,982 | 0.25 | -14,484.82 | -41,7% | |
| 2025-10-03 | Klichinsky Michael | Officer, Chief Scientific Officer | Open Market Sale | -119,347 | 0.26 | -31,077.96 | -89,5% | |
| 2025-10-02 | Klichinsky Michael | Officer, Chief Scientific Officer | Open Market Sale | -200,000 | 0.25 | -50,860.00 | -146,5% | |
| 2025-10-01 | Klichinsky Michael | Officer, Chief Scientific Officer | Open Market Sale | -165,000 | 0.26 | -42,405.00 | -122,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.